JP2006519610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006519610A5 JP2006519610A5 JP2006507095A JP2006507095A JP2006519610A5 JP 2006519610 A5 JP2006519610 A5 JP 2006519610A5 JP 2006507095 A JP2006507095 A JP 2006507095A JP 2006507095 A JP2006507095 A JP 2006507095A JP 2006519610 A5 JP2006519610 A5 JP 2006519610A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid compound
- ephb4
- ephrinb2
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 nucleic acid compound Chemical class 0.000 claims 99
- 108020004707 nucleic acids Proteins 0.000 claims 99
- 102000039446 nucleic acids Human genes 0.000 claims 99
- 210000004027 cell Anatomy 0.000 claims 32
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 238000000034 method Methods 0.000 claims 20
- 230000004962 physiological condition Effects 0.000 claims 18
- 108091030071 RNAI Proteins 0.000 claims 13
- 230000009368 gene silencing by RNA Effects 0.000 claims 13
- 230000033115 angiogenesis Effects 0.000 claims 11
- 230000000692 anti-sense effect Effects 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 230000004544 DNA amplification Effects 0.000 claims 3
- 102000006396 Ephrin-B2 Human genes 0.000 claims 3
- 108010044090 Ephrin-B2 Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000002255 enzymatic effect Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000008298 phosphoramidates Chemical class 0.000 claims 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 208000009056 telangiectasis Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000030797 EphB4 Receptor Human genes 0.000 claims 1
- 108010055323 EphB4 Receptor Proteins 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000001513 prostate squamous cell carcinoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000004862 vasculogenesis Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45430003P | 2003-03-12 | 2003-03-12 | |
| US45443203P | 2003-03-12 | 2003-03-12 | |
| US60/454,300 | 2003-03-12 | ||
| US60/454,432 | 2003-03-12 | ||
| PCT/US2004/007491 WO2004080418A2 (en) | 2003-03-12 | 2004-03-12 | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006519610A JP2006519610A (ja) | 2006-08-31 |
| JP2006519610A5 true JP2006519610A5 (cg-RX-API-DMAC7.html) | 2007-05-10 |
| JP4762889B2 JP4762889B2 (ja) | 2011-08-31 |
Family
ID=32994555
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507095A Expired - Fee Related JP4762889B2 (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
| JP2006507160A Pending JP2006521111A (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
| JP2011157200A Pending JP2011256179A (ja) | 2003-03-12 | 2011-07-15 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507160A Pending JP2006521111A (ja) | 2003-03-12 | 2004-03-12 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
| JP2011157200A Pending JP2011256179A (ja) | 2003-03-12 | 2011-07-15 | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US7585967B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1605961A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP4762889B2 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2004220525B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2518898A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2004080425A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| AU2002951409A0 (en) * | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
| JP2006507256A (ja) | 2002-09-24 | 2006-03-02 | ザ バーナム インスティチュート | Eph受容体活性を調節する新規薬剤 |
| EP1605961A4 (en) | 2003-03-12 | 2009-11-11 | Vasgene Therapeutics Inc | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH |
| US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| KR20120123619A (ko) | 2004-03-12 | 2012-11-08 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
| WO2005090406A2 (en) * | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| JP2007320850A (ja) * | 2004-08-24 | 2007-12-13 | Kyowa Hakko Kogyo Co Ltd | 抗エフリンb2抗体 |
| WO2006034455A2 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| AU2005286663A1 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
| DE102004054016A1 (de) * | 2004-11-09 | 2006-05-11 | Robert Bosch Gmbh | Steuergerät zum Steuern und/oder regeln mindestens einer Fahrzeugfunktion |
| CA2587854C (en) * | 2004-11-18 | 2014-01-21 | The Board Of Trustees Of The University Of Illinois | Multicistronic sirna constructs to inhibit tumors |
| WO2006074392A2 (en) * | 2005-01-06 | 2006-07-13 | Genentech, Inc. | Cancer prognostic, diagnostic and treatment methods |
| WO2006081418A2 (en) * | 2005-01-27 | 2006-08-03 | The Burnham Institute | Ephb receptor-binding peptides |
| FR2889200B1 (fr) | 2005-07-27 | 2008-01-04 | Inst Vaisseaux Et Du Sang Ass | Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique |
| EP1937291A2 (en) * | 2005-09-23 | 2008-07-02 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment of prevention of viral infections |
| RU2451031C2 (ru) | 2006-01-20 | 2012-05-20 | Дженентек, Инк. | Антитела к эфрину в2 и способы их применения |
| JP2010500011A (ja) | 2006-08-08 | 2010-01-07 | ガンサー ハートマン | 5’リン酸オリゴヌクレオチドの構造および使用 |
| US20110052667A1 (en) * | 2007-06-28 | 2011-03-03 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
| CN102083861B (zh) * | 2007-08-13 | 2016-04-13 | 瓦斯基因治疗公司 | 使用结合EphB4的人源化抗体的癌症治疗 |
| US8357501B2 (en) | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
| ATE554186T1 (de) * | 2007-11-29 | 2012-05-15 | Molecular Health Gmbh | Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| WO2012112434A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using retargeted endopeptidases |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Fgf4遺伝子増幅腫瘍の医薬組成物 |
| US12655390B2 (en) | 2016-12-14 | 2026-06-16 | Shinshu University | Chimeric antigen receptor gene-modified lymphocyte having cytocidal effect |
| WO2018110374A1 (ja) * | 2016-12-14 | 2018-06-21 | 国立大学法人信州大学 | 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球 |
| US20200224239A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Functional analysis of cancer cells |
| US12560590B2 (en) | 2019-01-23 | 2026-02-24 | Massachusetts Institute Of Technology | Rapid analysis of live cells |
| AU2020241963B2 (en) | 2019-03-17 | 2026-07-02 | Vasgene Therapeutics Inc | Treatment of cancers using sEphB4-HSA fusion proteins |
| WO2021242637A1 (en) * | 2020-05-28 | 2021-12-02 | Cytobay Inc. | Cytopathological staining |
| EP4105328A1 (en) * | 2021-06-15 | 2022-12-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression |
| US20250339504A1 (en) * | 2022-05-18 | 2025-11-06 | National Cancer Center | Cancer vaccine with use of common cancer antigen cocktail, tcr/car-t cell therapeutic, companion diagnostic method, and method for diagnosing risk of cancer onset by detecting circulating tumor cells |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| ATE278019T1 (de) | 1991-06-21 | 2004-10-15 | Inst Medical W & E Hall | Neuartige rezeptor-typ tyrosinkinase und deren verwendung |
| JPH07504813A (ja) | 1992-01-22 | 1995-06-01 | ニユー・イングランド・デイーコネス・ホスピタル | 新規蛋白質チロシンキナーゼ類 |
| US6331302B1 (en) * | 1992-01-22 | 2001-12-18 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US5635177A (en) | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| FI952328A7 (fi) | 1992-11-13 | 1995-07-10 | Amgen Inc | eck-respetorin lignandeja |
| US5824303A (en) * | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
| US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
| ES2152753B1 (es) | 1993-03-29 | 2001-09-01 | Ct Investig Energeticas Ciemat | Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6303769B1 (en) * | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5864020A (en) * | 1994-07-20 | 1999-01-26 | Genentech, Inc. | HTK ligand |
| AU3144195A (en) | 1994-07-26 | 1996-02-22 | Rutgers, The State University Of New Jersey | Human brain specific kinase |
| US5795734A (en) | 1994-09-19 | 1998-08-18 | President And Fellows Of Harvard College | EPH receptor ligands, and uses related thereto |
| WO1996013518A1 (en) | 1994-10-27 | 1996-05-09 | Genentech, Inc. | Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| WO1996026958A2 (en) | 1995-02-27 | 1996-09-06 | President And Fellows Of Harvard College | Eph RECEPTOR LIGAND ELF-2 |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| PT848755E (pt) | 1995-09-08 | 2003-12-31 | Genentech Inc | Proteina relacionada com o vegf |
| US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
| AUPN727795A0 (en) | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | A novel receptor-type tyrosine kinase and use thereof |
| US6696557B1 (en) * | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| CA2259157A1 (en) * | 1996-07-05 | 1998-01-15 | Mount Sinai Hospital Corporation | Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| AU6887698A (en) | 1997-04-08 | 1998-10-30 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
| US6440954B1 (en) * | 1997-04-18 | 2002-08-27 | President And Fellows Of Harvard College | Inhibition of vascular smooth muscle cell proliferation |
| US6555321B1 (en) * | 1997-08-19 | 2003-04-29 | Vanderbilt University | Methods for determining cell responses through EphB receptors |
| EP1019080A2 (en) | 1997-10-02 | 2000-07-19 | Leukosite, Inc. | Modulation of lerk-2-mediated cell adhesion |
| DE69921102T2 (de) * | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
| US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| AU8788998A (en) | 1998-10-02 | 2000-04-06 | Universite Paris 7 | Vascular specific regulatory elements contained in the desmin 5' flanking region |
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| ES2242437T3 (es) * | 1998-11-20 | 2005-11-01 | Genentech, Inc. | Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares. |
| US6150162A (en) * | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
| US6770633B1 (en) * | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| EP1246637A2 (en) | 2000-01-06 | 2002-10-09 | The Hospital for Sick Children | Methods of modulation of the immune system |
| CA2400573A1 (en) * | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals Inc. | Alteration of cellular behavior by antisense modulation of mrna processing |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2003530871A (ja) | 2000-04-21 | 2003-10-21 | アムジエン・インコーポレーテツド | インテグリン/接着因子アンタゴニスト |
| US6271030B1 (en) * | 2000-06-14 | 2001-08-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of C/EBP beta expression |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| CA2417982A1 (en) | 2000-08-03 | 2002-02-14 | The University Of Utah Research Foundation | Manipulation of arterial-venous identity |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| WO2002026827A1 (en) | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
| US7136808B2 (en) * | 2000-10-20 | 2006-11-14 | Microsoft Corporation | Detection and correction of errors in german grammatical case |
| DE60127291T2 (de) * | 2000-11-20 | 2007-12-20 | California Institute Of Technology, Pasadena | Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung |
| CN100523215C (zh) * | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US6958140B2 (en) | 2001-01-26 | 2005-10-25 | Regeneron Pharmaceuticals, Inc. | Methods of imaging and targeting vasculature |
| US20040132634A1 (en) | 2001-01-31 | 2004-07-08 | Frank Sicheri | Compositions and methods for regulating the kinase domain of receptor tyrosine kinases |
| JP2004517638A (ja) | 2001-02-02 | 2004-06-17 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 機能的核酸の同定方法 |
| CA2442092A1 (en) * | 2001-03-26 | 2002-10-17 | Ribozyme Pharmaceuticals, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| WO2002079382A2 (en) | 2001-03-30 | 2002-10-10 | President And Fellows Of Harvard College | B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use |
| EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| JP2005500025A (ja) * | 2001-05-29 | 2005-01-06 | サーナ・セラピューティクス・インコーポレイテッド | 女性生殖疾病及び状態の核酸に基づく調節 |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1409549A4 (en) * | 2001-06-20 | 2007-10-24 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS |
| US20040247592A1 (en) * | 2001-07-03 | 2004-12-09 | Roifman Chaim M. | Ephrin and eph receptor mediated immune modulation |
| JP3876656B2 (ja) * | 2001-07-13 | 2007-02-07 | 住友金属工業株式会社 | 管用ねじ継手 |
| JP2005531281A (ja) * | 2001-11-02 | 2005-10-20 | ファイザー・プロダクツ・インク | 肺癌の治療および診断 |
| US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
| EP1519956B1 (en) | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| EP1575509B1 (en) | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| US20040110150A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of Ephrin-B2 expression |
| WO2004020468A2 (en) | 2002-08-28 | 2004-03-11 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| AU2003260169B9 (en) * | 2002-09-16 | 2011-06-09 | The Queen Elizabeth Hospital Research Foundation Inc. | Methods for regulating cancer |
| AU2002951409A0 (en) | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US7250289B2 (en) * | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
| EP1605961A4 (en) * | 2003-03-12 | 2009-11-11 | Vasgene Therapeutics Inc | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH |
| NZ543122A (en) * | 2003-03-24 | 2008-07-31 | Sequoia Pharmaceuticals Inc | An HIV fusion inhibitor peptide covalently linked to a blood protein |
| EP1618184A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION |
| EP1617864A4 (en) | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING |
| WO2005048917A2 (en) | 2003-06-06 | 2005-06-02 | Medimmune, Inc. | Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer |
| DK1677735T3 (da) * | 2003-10-17 | 2014-10-27 | Joslin Diabetes Center Inc | Fremgangsmåder og sammensætninger til modulering af adipocytfunktion |
| KR20060135671A (ko) | 2003-11-20 | 2006-12-29 | 메디뮨 인코포레이티드 | EphA2 작동성 모노클로날 항체 및 이의 사용 방법 |
| WO2005090406A2 (en) | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
-
2004
- 2004-03-12 EP EP20040720444 patent/EP1605961A4/en not_active Withdrawn
- 2004-03-12 CA CA002518898A patent/CA2518898A1/en not_active Abandoned
- 2004-03-12 CA CA002518912A patent/CA2518912A1/en not_active Abandoned
- 2004-03-12 WO PCT/US2004/007755 patent/WO2004080425A2/en not_active Ceased
- 2004-03-12 AU AU2004220525A patent/AU2004220525B2/en not_active Ceased
- 2004-03-12 WO PCT/US2004/007491 patent/WO2004080418A2/en not_active Ceased
- 2004-03-12 JP JP2006507095A patent/JP4762889B2/ja not_active Expired - Fee Related
- 2004-03-12 EP EP04720327A patent/EP1606305A4/en not_active Withdrawn
- 2004-03-12 AU AU2004220459A patent/AU2004220459B2/en not_active Ceased
- 2004-03-12 JP JP2006507160A patent/JP2006521111A/ja active Pending
- 2004-03-12 US US10/800,077 patent/US7585967B2/en not_active Expired - Fee Related
- 2004-03-12 US US10/800,350 patent/US7862816B2/en not_active Expired - Fee Related
-
2006
- 2006-10-06 US US11/544,855 patent/US8063183B2/en not_active Expired - Fee Related
-
2009
- 2009-09-01 US US12/552,185 patent/US20100093831A1/en not_active Abandoned
-
2010
- 2010-11-01 AU AU2010238577A patent/AU2010238577B2/en not_active Ceased
- 2010-11-23 US US12/952,593 patent/US20110129482A1/en not_active Abandoned
-
2011
- 2011-07-15 JP JP2011157200A patent/JP2011256179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Massagué et al. | Metastatic colonization by circulating tumour cells | |
| Sen et al. | Micromanaging vascular biology: tiny microRNAs play big band | |
| JP4762889B2 (ja) | 血管形成及び腫瘍成長を阻止するための核酸化合物 | |
| JP2019500347A5 (cg-RX-API-DMAC7.html) | ||
| JP7553036B2 (ja) | snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| Nosrati et al. | Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA | |
| CA2817371A1 (en) | Microrna inhibitors comprising locked nucleotides | |
| KR20220113999A (ko) | 종양 마커 및 치료 표적으로서의 긴 비-코딩 rna letn | |
| Gandhi et al. | The role of long noncoding RNAs in ocular angiogenesis and vascular oculopathy | |
| Kohnken et al. | MicroRNAs in cutaneous T-cell lymphoma: the future of therapy | |
| Mthembu et al. | Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers | |
| US20160362693A1 (en) | Reagents and Methods for Treating Cancer | |
| JP5891173B2 (ja) | がん幹細胞を含むまたはそれに由来するがんの治療、予防および診断のための方法および組成物 | |
| WO2021010449A1 (ja) | Rna分子、キメラ型na分子、二本鎖rna分子、および二本鎖キメラ型na分子 | |
| CN105734121A (zh) | 乙醛脱氢酶1a3及其编码基因作为结直肠癌侵袭转移预防或治疗靶点的应用 | |
| US11149274B2 (en) | Methods and compositions for managing vascular conditions | |
| JP2023530234A5 (cg-RX-API-DMAC7.html) | ||
| Farhadi et al. | The potential role of circular RNAs in regulating p53 in different types of cancers | |
| JPWO2006132204A1 (ja) | 転写因子デコイ | |
| KR20130014840A (ko) | miR-636을 이용한 간암 치료 및 진단 방법 | |
| Song et al. | Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme | |
| CN110358765A (zh) | 抑制人TNFAIP1基因表达的siRNA及其应用 | |
| JP7498448B2 (ja) | SNHG12遺伝子に由来するncRNAの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| CN113373177A (zh) | 一种提高胶质母细胞瘤替莫唑胺疗效的方法 | |
| CN122012503A (zh) | 同时靶向癌基因pttg1和stmn1的抑癌小干扰rna及其应用 |